Cargando…
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation
AIMS/HYPOTHESIS: Sodium–glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) constitute a novel class of glucose-lowering (type 2) kidney-targeted agents. We recently reported that the SGLT2i empagliflozin (EMPA) reduced cardiac cytosolic Na(+) ([Na(+)](c)) and cytosolic Ca(2+) ([Ca(2+)](c)) concentr...
Autores principales: | Uthman, Laween, Baartscheer, Antonius, Bleijlevens, Boris, Schumacher, Cees A., Fiolet, Jan W. T., Koeman, Anneke, Jancev, Milena, Hollmann, Markus W., Weber, Nina C., Coronel, Ruben, Zuurbier, Coert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448958/ https://www.ncbi.nlm.nih.gov/pubmed/29197997 http://dx.doi.org/10.1007/s00125-017-4509-7 |
Ejemplares similares
-
Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na(+)/H(+) exchanger 1: persistent inhibition under various experimental conditions
por: Zuurbier, Coert J, et al.
Publicado: (2021) -
Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits
por: Baartscheer, Antonius, et al.
Publicado: (2016) -
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
por: Uthman, Laween, et al.
Publicado: (2018) -
The Driving Force of the Na(+)/Ca(2+)-Exchanger during Metabolic Inhibition
por: Baartscheer, Antonius, et al.
Publicado: (2011) -
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
por: Chen, Sha, et al.
Publicado: (2023)